A Phase III Trial of the Study of Endocrine Therapy used as a Cytoreductive and Cytostatic Agent Prior to Radiation Therapy in Good Prognosis Locally Confined Adenocarcinoma of the Prostate
David McGowan, MD
Date Closed to Accrual
April 30 2001
Date of Study Termination
May 14 2018
To evaluate whether a combination of Zoladex and flutamide used as cytoreductive agents prior to and during definitive radiation therapy improves overall survival over radiation therapy alone in locally confined carcinomas of the prostate
Data Collection Notice:
Data for this trial is being collected via the NRG/RTOG Data Center.
Histologically confirmed locally confined adenocarcinoma of the prostate.
Clinical stages T1b-2b.
No involved nodes.
No distant metastases.
Karnofsky performance status > = 70.
No prior antiandrogen therapy (except as allowed by Section 3.1.5), radiation or chemotherapy
Patient Study Webpage
There is no available patient study webpage available for this trial at this time.